动物造模 z-bio 2021-02-24 298

　　Purpose: Erlotinib is a new type of target drug for the treatment of non-small cell lung cancer. It has been widely used clinically in recent years, but it has many side effects. Among them, rash is the most common. Common and most common. It is difficult for the patient to accept it. This study observed the changes of mouse epidermis, pathology and immunohistochemistry before and after Tarceva application, replicated the animal model of rash caused by Tarceva, and provided a model for the treatment of skin rash with clinical topical medication. The purpose is to do .

　　Method: 20 BALB/c female mice were used and randomly divided into 4 groups. The experimental group (group II, group III, and group IV) took 100 mg/kg Tarceva solution at a concentration of 10 g/L, and the control group (group I) took the same amount of deionized water every day. . Twenty-four hours before the administration, hair was removed from the head, neck, back and buttocks of the mice, and after the experiment, the neck, back, and buttocks skin were cut and observed in the experimental group and the control group. Changes in macroscopic skin, pathological sections, immunohistochemistry, etc.

　　Results: (1) Five aspects of the four groups of mice: the date of hair regeneration, the date of complete hair regeneration, the time of peeling, the time of appearance of rash and the number of enlarged pores were statistically significant in five aspects (P0.05).

　　Conclusion: (1) This experiment supports the view of many researchers that the rash caused by EGFRI is an inflammatory reaction. (2) The skin rash model is reliable, practical and reproducible. "Many animal models of skin rash have been established, which can be promoted for clinical, experimental and research purposes.